Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

News Conference News TCT 2017

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Yael L. Maxwell

November 09, 2017

Presentation TCT 2017

Point A Multi-Device Lesion-Specific Approach is Preferred!

Presenter: Michael J. Reardon

November 01, 2017

Presentation TCT 2017

The Compelling Saga of Stroke after TAVR: Key Messages From NeuroARC

Presenter: Michael J. Reardon, Didier Tchetche, Alexandra J. Lansky

October 31, 2017

Presentation TCT 2017

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Presenter: Michael J. Reardon

October 31, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

News Daily News

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

Caitlin E. Cox

September 29, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

Presentation TVT 2017

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Michael J. Reardon

June 16, 2017

Presentation TVT 2017

The Portico TAVR System: A Cool Case, New Technology, and Clinical Program Updates

Presenter: Martin B. Leon, Michael J. Reardon, Raj Makkar

June 16, 2017

Presentation TVT 2017

The ACURATE TAVR System: A Cool Case, New Technology, and Clinical Program Updates

Presenter: Martin B. Leon, Michael J. Reardon, Thomas Walther

June 16, 2017

Presentation TVT 2017

The LOTUS TAVR System: A Cool Case, New Technology (Including EDGE), and Clinical Program Updates

Presenter: Michael J. Reardon

June 16, 2017

Presentation TVT 2017

The REPRISE III LBCT: A Randomized Trial Comparing LOTUS vs Self-Expanding CoreValve in High-Risk Aortic Stenosis Patients

Presenter: Axel Linke, Jeffrey J. Popma, Michael J. Reardon

June 15, 2017

Presentation SWVS 2017

Cases: The Good, The Bad and The Ugly

Presenter: Michael J. Reardon

May 07, 2017

Presentation SWVS 2017

Extreme Sizing: The Very Small and the Very Large

Presenter: Michael J. Reardon

May 06, 2017

Presentation SWVS 2017

TAVR: Evolving Risk Assessment and Expectations

Presenter: Michael J. Reardon

May 06, 2017

Presentation SWVS 2017

Heart Valve Dysfunction With ESRD: Options and Expectations

Presenter: Michael J. Reardon

May 06, 2017

Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: First Results from the SURTAVI Clinical Trial

Presentation ACC 2017

First Results from the SURTAVI Clinical Trial

Presenter: Michael J. Reardon

March 17, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

Advertisement

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Point A Multi-Device Lesion-Specific Approach is Preferred!

The Compelling Saga of Stroke after TAVR: Key Messages From NeuroARC

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

The Portico TAVR System: A Cool Case, New Technology, and Clinical Program Updates

The ACURATE TAVR System: A Cool Case, New Technology, and Clinical Program Updates

The LOTUS TAVR System: A Cool Case, New Technology (Including EDGE), and Clinical Program Updates

The REPRISE III LBCT: A Randomized Trial Comparing LOTUS vs Self-Expanding CoreValve in High-Risk Aortic Stenosis Patients

Cases: The Good, The Bad and The Ugly

Extreme Sizing: The Very Small and the Very Large

TAVR: Evolving Risk Assessment and Expectations

Heart Valve Dysfunction With ESRD: Options and Expectations

First Results from the SURTAVI Clinical Trial

Live From Washington: ACC 2017, Day One

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content